HK1201190A1 - 減少炎症介質釋放的方法和可用於該方法的肽 - Google Patents

減少炎症介質釋放的方法和可用於該方法的肽

Info

Publication number
HK1201190A1
HK1201190A1 HK15101730.6A HK15101730A HK1201190A1 HK 1201190 A1 HK1201190 A1 HK 1201190A1 HK 15101730 A HK15101730 A HK 15101730A HK 1201190 A1 HK1201190 A1 HK 1201190A1
Authority
HK
Hong Kong
Prior art keywords
methods
inflammatory mediators
peptides useful
attenuating
release
Prior art date
Application number
HK15101730.6A
Other languages
English (en)
Inventor
.帕里克
Original Assignee
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceuticals Ltd filed Critical Biomarck Pharmaceuticals Ltd
Publication of HK1201190A1 publication Critical patent/HK1201190A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK15101730.6A 2006-07-26 2015-02-16 減少炎症介質釋放的方法和可用於該方法的肽 HK1201190A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83323906P 2006-07-26 2006-07-26

Publications (1)

Publication Number Publication Date
HK1201190A1 true HK1201190A1 (zh) 2015-08-28

Family

ID=38982357

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09104579.2A HK1125793A1 (zh) 2006-07-26 2009-05-19 減弱釋放炎性介質的肽
HK15101730.6A HK1201190A1 (zh) 2006-07-26 2015-02-16 減少炎症介質釋放的方法和可用於該方法的肽

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK09104579.2A HK1125793A1 (zh) 2006-07-26 2009-05-19 減弱釋放炎性介質的肽

Country Status (22)

Country Link
US (6) US8999915B2 (zh)
EP (2) EP2053915B1 (zh)
JP (2) JP5378998B2 (zh)
KR (1) KR101599894B1 (zh)
CN (2) CN103990111B (zh)
AU (1) AU2007279193B2 (zh)
BR (1) BRPI0714953A2 (zh)
CA (2) CA2658949C (zh)
DK (2) DK2053915T3 (zh)
ES (2) ES2725599T3 (zh)
HK (2) HK1125793A1 (zh)
HR (1) HRP20140587T1 (zh)
IL (1) IL196667A (zh)
MX (1) MX2009000975A (zh)
NO (1) NO20090304L (zh)
PL (2) PL2053915T3 (zh)
PT (1) PT2053915E (zh)
RU (1) RU2423376C2 (zh)
SG (2) SG173411A1 (zh)
SI (1) SI2053915T1 (zh)
WO (1) WO2008014414A2 (zh)
ZA (1) ZA200900550B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101146545B (zh) 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽
CA2766157A1 (en) * 2009-06-25 2010-12-29 Hua Gong Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) * 2009-11-13 2011-05-19 North Carolina State University Methods of modulating mesenchymal stem cells
ES2714863T3 (es) 2013-04-05 2019-05-30 Biomarck Pharmaceuticals Ltd Péptidos del inhibidor de MARCKS para la inhibición de metástasis
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
WO2015095789A2 (en) 2013-12-20 2015-06-25 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) * 2019-02-20 2020-11-20 한국외국어대학교 연구산학협력단 염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
WO2023212443A1 (en) * 2022-04-25 2023-11-02 Biomarck Pharmaceuticals, Ltd. Peptides and methods of use thereof in treating skin diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61265341A (ja) * 1985-05-17 1986-11-25 Kawasaki Heavy Ind Ltd V型エンジンのシリンダ−ブロツク構造
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) * 1988-02-08 1990-10-30 The General Hospital Corporation Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
AU642133B2 (en) 1988-11-18 1993-10-14 Board Of Regents Of The University Of Washington, The HDL-binding proteins
US5223421A (en) * 1989-10-25 1993-06-29 The General Hospital Corporation Identification of methionine Nα-acetyltransferase
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
WO1993000353A1 (en) 1991-06-20 1993-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
WO1995027496A1 (en) 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
DE60014856T2 (de) * 1999-02-24 2006-02-02 North Carolina State University Zusammensetzungen zur modulierung der schleimsekretion
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
DK1104758T3 (da) 1999-12-03 2003-10-20 Pfizer Prod Inc Acetylenderivativer som anti-inflammatoriske/analgesiske lægemidler
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
ATE519493T1 (de) 2001-06-26 2011-08-15 Univ North Carolina State Blockierendes peptid für die sekretion von entzündungszellen
JP2004049133A (ja) 2002-07-22 2004-02-19 Kumamoto Technology & Industry Foundation N−ミリストイルトランスフェラーゼ活性の測定方法
US7598080B2 (en) 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
US7408030B2 (en) 2005-01-13 2008-08-05 North Carolina State University Purification of immunoglobulins using affinity chromatography and peptide ligands
CN101146545B (zh) 2005-01-20 2012-12-26 拜欧马克医药有限公司 基于mans的结构的粘蛋白分泌过多抑制剂和应用方法
CN103990111B (zh) 2006-07-26 2016-08-31 拜欧马克医药有限公司 减少炎症介质释放的方法和可用于该方法的肽

Also Published As

Publication number Publication date
CA2658949A1 (en) 2008-01-31
PL2722052T3 (pl) 2019-08-30
WO2008014414A3 (en) 2008-09-25
SG10201500418QA (en) 2015-03-30
US8999915B2 (en) 2015-04-07
CA2842219C (en) 2017-07-11
CN103990111B (zh) 2016-08-31
CN101516190B (zh) 2014-06-11
JP5819889B2 (ja) 2015-11-24
EP2053915A4 (en) 2011-06-08
EP2053915A2 (en) 2009-05-06
KR20090037487A (ko) 2009-04-15
US20090203620A1 (en) 2009-08-13
RU2423376C2 (ru) 2011-07-10
PT2053915E (pt) 2014-08-25
CA2842219A1 (en) 2008-01-31
JP2009544737A (ja) 2009-12-17
IL196667A (en) 2017-04-30
HRP20140587T1 (hr) 2014-11-21
EP2722052B1 (en) 2019-03-20
SG173411A1 (en) 2011-08-29
HK1125793A1 (zh) 2009-08-21
US20230293629A1 (en) 2023-09-21
US9827287B2 (en) 2017-11-28
ES2725599T3 (es) 2019-09-25
SI2053915T1 (sl) 2014-10-30
CA2658949C (en) 2014-04-22
US20180036367A1 (en) 2018-02-08
ZA200900550B (en) 2010-03-31
AU2007279193A1 (en) 2008-01-31
CN101516190A (zh) 2009-08-26
MX2009000975A (es) 2009-04-07
RU2009106673A (ru) 2010-09-10
US20160030509A1 (en) 2016-02-04
KR101599894B1 (ko) 2016-03-04
BRPI0714953A2 (pt) 2013-07-16
PL2053915T3 (pl) 2014-12-31
ES2488092T3 (es) 2014-08-26
JP5378998B2 (ja) 2013-12-25
EP2722052A1 (en) 2014-04-23
JP2013241428A (ja) 2013-12-05
EP2053915B1 (en) 2014-06-11
CN103990111A (zh) 2014-08-20
DK2722052T3 (en) 2019-04-29
US20210260154A1 (en) 2021-08-26
IL196667A0 (en) 2011-08-01
US20200138898A1 (en) 2020-05-07
NO20090304L (no) 2009-04-21
AU2007279193B2 (en) 2011-12-01
DK2053915T3 (da) 2014-06-30
WO2008014414A2 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
HK1201190A1 (zh) 減少炎症介質釋放的方法和可用於該方法的肽
IL193846A0 (en) Methods for regulating inflammatory mediators and peptides useful therein
EP1899480A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS
HK1139191A1 (en) Laccase mediators and methods of use
WO2009134389A9 (en) An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2355717A4 (en) METHOD AND SYSTEMS FOR DETECTING AND REMOVING HARN STONES FROM BODY HOLLOWS
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
EP2094085A4 (en) ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL197781A0 (en) Lyophilization methods and apparatuses
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA200905273B (en) Compositions and methods of use of phorbol esters
EP2069467A4 (en) SEPARATION COMPOSITIONS AND METHOD FOR THEIR USE
EP2038402A4 (en) DEVICES AND METHODS FOR CRYOPRESERVATION OF CELLS
EP1943875A4 (en) HEADPHONES AND METHOD OF USE
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
IL193514A0 (en) Antibodies to egfl7 and methods for their use
ZA200810831B (en) Formulations with feruloyl glycerides and methods of preparation
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
IL192552A0 (en) Dnt-succinate and methods of preparation thereof
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use